# A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

> **NCT03398135** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 1242 (actual)

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

- **DRUG:** risankizumab
- **DRUG:** placebo for risankizumab

## Key facts

- **NCT ID:** NCT03398135
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-28
- **Primary completion:** 2028-09
- **Final completion:** 2029-02
- **Target enrollment:** 1242 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03398135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03398135, "A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03398135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*